ScoreWhy is Kilitch Drugs (India) Ltd ?
1
Poor Management Efficiency with a low ROE of 8.85%
- The company has been able to generate a Return on Equity (avg) of 8.85% signifying low profitability per unit of shareholders funds
2
Company has a low Debt to Equity ratio (avg) at 0.01 times
3
Healthy long term growth as Net Sales has grown by an annual rate of 28.00% and Operating profit at 59.44%
4
Positive results in Dec 25
- CASH AND CASH EQUIVALENTS(HY) Highest at Rs 33.10 cr
5
Technical trend is Sideways signifying no clear price momentum
- The technical trend has deteriorated from on 18-Jun-26
6
With ROE of 10.8, it has a Fair valuation with a 2.3 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -18.67%, its profits have risen by 14.6% ; the PEG ratio of the company is 3.8
7
Despite the size of the company, domestic mutual funds hold only 0% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Kilitch Drugs should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Kilitch Drugs for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Kilitch Drugs
-18.67%
-0.25
75.27%
Sensex
-4.95%
-0.37
13.26%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
28.00%
EBIT Growth (5y)
59.44%
EBIT to Interest (avg)
4.88
Debt to EBITDA (avg)
1.79
Net Debt to Equity (avg)
0.07
Sales to Capital Employed (avg)
0.72
Tax Ratio
23.69%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
10.97%
ROE (avg)
8.85%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
21
Industry P/E
34
Price to Book Value
2.25
EV to EBIT
19.72
EV to EBITDA
17.77
EV to Capital Employed
2.17
EV to Sales
2.76
PEG Ratio
3.83
Dividend Yield
NA
ROCE (Latest)
11.00%
ROE (Latest)
10.79%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend1What is working for the Company
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 33.10 cr
-12What is not working for the Company
PBT LESS OI(Q)
At Rs 4.07 cr has Fallen at -27.0% (vs previous 4Q average
PAT(Q)
At Rs 4.43 cr has Fallen at -35.8% (vs previous 4Q average
INTEREST(9M)
At Rs 4.12 cr has Grown at 24.47%
DEBT-EQUITY RATIO(HY)
Highest at 0.32 times
Loading Valuation Snapshot...
Here's what is working for Kilitch Drugs
Cash and Cash Equivalents - Half Yearly
Highest at Rs 33.10 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Kilitch Drugs
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 4.07 cr has Fallen at -27.0% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 5.57 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 4.43 cr has Fallen at -35.8% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 6.90 CrMOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
Interest - Nine Monthly
At Rs 4.12 cr has Grown at 24.47%
over preceding nine months periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
Debt-Equity Ratio - Half Yearly
Highest at 0.32 times
in the last five half yearly periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
